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Abstract: Cartilage loss leads to osteoarthritis, the most common cause of disability for which 32 
there is no cure. Cartilage regeneration, therefore, is a priority in medicine. We report that agrin 33 
is a potent chondrogenic factor and that a single intra-articular administration of agrin induced 34 
long-lasting regeneration of critical-size osteochondral defects in mice, with restoration of tissue 35 
architecture and bone-cartilage interface. Agrin attracted joint resident progenitor cells to the site 36 
of injury and, through simultaneous activation of CREB and suppression of canonical WNT 37 
signaling downstream of β-catenin, induced expression of the chondrogenic stem cell marker 38 
GDF5 and differentiation into stable articular chondrocytes, forming stable articular cartilage.  In 39 
sheep, an agrin-containing collagen gel resulted in long-lasting regeneration of bone and 40 
cartilage, which promoted increased ambulatory activity. Our findings support the therapeutic 41 




Articular cartilage overlies subchondral bone at the joint surface and enables the frictionless 44 
movement of joints. Whereas bone has a high turnover and heals well, cartilage is avascular, has 45 
a low turnover, and often fails to repair after injury (1). This results in further cartilage loss and 46 
osteoarthritis, the most common form of arthritis, which causes pain and disability. Currently, 47 
there is no pharmacological therapy to restore cartilage or slow cartilage loss. Osteoarthritis is 48 
therefore, along with cardiovascular disease, the leading cause of chronic disability, costing around 49 
1.5-2% of the gross domestic product (GDP) for westernized countries (2). 50 
Joint surface defects are common(3, 4) and, when exceeding a critical size, heal poorly. When 51 
successful, the repair of small osteochondral defects involves trafficking of specialized 52 
mesenchymal stem cells (MSCs) ontogenetically derived from the growth differentiation factor 5 53 
(GDF5)-expressing cells of the embryonic joint interzone to the injury site (5, 6). During 54 
embryonic development, MSCs are recruited from SOX9-expressing progenitor cells, transiently 55 
express GDF5, and give rise to the articular cartilage, menisci, and ligaments (7). In adulthood, 56 
GDF5-lineage progenitor cells persist in the synovial membrane (SM-MSCs) (5, 6).  At the bottom 57 
of the defect, the repair cartilage is invaded by vessels and replaced by bone through endochondral 58 
bone formation, which proceeds towards the surface of the defect and stops at the level of the 59 
osteochondral junction (8–10). The most superficial layer of cartilage remains avascular and is 60 
resistant to endochondral bone formation (8, 9). Although this morphogenetic process takes place 61 
over several weeks in rodents and several months in humans, at the molecular level, the 62 
mesenchyme becomes patterned long before morphological changes become obvious (10). Such 63 
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patterning displays striking similarity to that of developing joints during embryonic 64 
morphogenesis. 65 
During skeletal development, the chondrogenic mesenchyme forming the skeletal templates 66 
becomes segmented by the joint interzones, where specific molecular markers — including 67 
WNT9A and GDF5, a member of the bone morphogenetic protein (BMP) family of morphogens 68 
— indicate the location where joints will form (6, 11–13). Through the process of cavitation, a 69 
fissure forms in the center of the joint interzones, eventually separating the skeletal elements. 70 
Meanwhile, the center of the cartilaginous template undergoes vascular invasion and chondrocytes 71 
undergo hypertrophy (expressing markers such as COL10A1) and are eventually replaced by bone. 72 
In the long bones, this process starts at the center (diaphysis) and proceeds towards the growth 73 
plate. Secondary ossification centers then form near the joints, in the epiphysis, to form the 74 
subchondral spongiosa containing bone marrow. The last few layers of chondrocytes closest to the 75 
joint cavity are spared from undergoing endochondral bone formation and form the articular 76 
cartilage. Lineage tracking experiments have established that the cells that form the articular 77 
cartilage (which persists throughout life), and those of the epiphyseal cartilage (destined to be 78 
replaced by bone), derive from distinct lineages, the former expressing GDF5 during embryonic 79 
joint formation (7, 12, 14).  80 
Members of the WNT family of morphogens (WNT4, WNT9A, and WNT16) are the earliest 81 
markers of the joint interzone (11, 15). The activation of the WNT pathway is both required (11, 82 
15) and sufficient to initiate the process of joint morphogenesis (15). The ectopic expression of 83 
Wnt9a was shown to trigger the ectopic expression of other joint interzone markers including Gdf5 84 
(11). During development, WNT signaling prevents the premature differentiation of the joint 85 
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interzone cells into mature chondrocytes. In adulthood, WNT signaling maintains a population of 86 
chondroprogenitors at the surface of the cartilage by preventing their differentiation into mature 87 
chondrocytes (12, 16). Due to its anti-chondrogenic effect however, excessive activation of WNT 88 
signaling within the joint predisposes to osteoarthritis (17, 18). 89 
WNTs are secreted signaling molecules involved in the regulation of cell proliferation, polarity, 90 
morphogenesis and differentiation (19) during both development and adulthood. In the absence of 91 
WNTs, the intracellular protein β-catenin is constitutively phosphorylated by GSK-3β and is 92 
degraded through the proteasome pathway. In the presence of so called “canonical” WNTs such 93 
as WNT1, WNT3A, or WNT8, the heterodimerization of frizzled (FZD) receptors and their co-94 
receptors LRP5 and 6 results in de-activation of GSK-3β and consequent stabilization of β-catenin. 95 
Stabilized β-catenin is transported to the nucleus where it interacts with the transcription factors 96 
TCF/LEF and activates transcription of target genes (19). Other WNT ligands, such as WNT5A, 97 
activate other calcium-dependent pathways, collectively denominated “non-canonical”. One of 98 
these non-canonical pathways is mediated by the intracellular kinase CaMKII and the transcription 99 
factor CREB(20). In many cells, including articular chondrocytes, activation of the non-canonical 100 
WNT signaling results in inhibition of the canonical pathway (21).  101 
In this study we report that AGRIN , a signaling proteoglycan (encoded by the gene AGRN) best 102 
known for its role at the neuromuscular junction, where it stabilizes the clustering of the 103 
acetylcholine receptors (22) by binding to its receptor LRP4 (23), is an orchestrator of repair 104 
morphogenesis at the joint surface by modulating multiple signaling pathways. Agrin is composed 105 
of a large N-terminal portion that binds to components of the basal membrane and a biologically 106 
active C-terminal portion encompassing three globular domains separated by EGF-like repeats 107 
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(24). Agrin is expressed in a splice isoform devoid of the y and z motifs, playing a role not only in 108 
differentiation of mature articular chondrocytes (25) but also in chondrogenesis and in the repair 109 
of osteochondral defects.  110 
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Results  111 
AGRIN is upregulated in injured cartilage and induces chondrogenesis in MSCs  112 
In the context of screening for genes upregulated after acute cartilage injury (26), we discovered 113 
that agrin was upregulated at the mRNA and protein level twenty-four hours after mechanical 114 
injury to human articular cartilage explants ex vivo (Fig. 1, A to C). AGRN mRNA was also 115 
upregulated in C28/I2 human chondrocytes by treatment with IL-1β (Fig. 1D) and TNF-α (Fig. 116 
1E), two inflammatory cytokines released by injured cartilage (26–29). Agrin upregulation in adult 117 
primary human articular chondrocytes after IL-1β treatment was confirmed as assessed by mining 118 
a publicly accessible gene expression dataset (30) (fig. S1A). Compared to green fluorescent 119 
protein (GFP), used hereafter as transfection control, agrin overexpression in human adult synovial 120 
membrane-derived mesenchymal stem cells (SM-MSCs) (5, 31) resulted in their differentiation 121 
into cartilage as assessed by increased production of cartilage-specific Alcian blue-positive 122 
extracellular matrix and upregulation of the cartilage master transcription factor SOX9 mRNA 123 
(Fig. 1, F and G). Together, these data show that agrin is upregulated in injured cartilage and 124 




Agrin induces chondrogenesis by suppressing WNT signaling downstream of β-catenin 127 
Next, we investigated the molecular pathway underlying the chondrogenic effect of agrin. The 128 
agrin receptor LDL receptor related protein 4 (LRP4) mediates chondrocytic differentiation in the 129 
murine chondrocytic cell line ATDC5 by inhibiting canonical WNT signaling (32). We found that 130 
overexpression of either LRP4 (Fig. 2A) or agrinitself (Fig. 2B), both in the absence and presence 131 
of WNT3A, in primary bovine chondrocytes upregulated SOX9 mRNA. LRP4 is known to bind to 132 
and mediate the function of WNT inhibitory molecules such as DKK1 and SOST (33); therefore, 133 
we investigated whether agrinis required for the chondrogenic function of LRP4. Silencing AGRN 134 
in C28I/2 chondrocytes prevented the SOX9 upregulation induced by LRP4 overexpression (Fig. 135 
2C). These data indicate that agrin is necessary for the chondrogenic effects of LRP4. Agrin 136 
silencing did not alter expression of DKK1 mRNA (fig. S1B). SOST is not expressed in articular 137 
chondrocytes and was not detected by PCR. 138 
Canonical WNT signaling is known to suppress chondrogenesis (12, 16). Agrin overexpression 139 
blocked the capacity of WNT3A and WNT9A to activate the WNT/β-catenin-dependent reporter 140 
assay TOPFlash (34) (Fig. 2, D and E). Overexpression of either LRP4 or agrin suppressed 141 
TOPFlash activation in a WNT3A dose-response curve and co-overexpression of LRP4 and agrin 142 
was synergisticfurther inhibited TOPFlash activation (Fig. 2F). Moreover, agrin failed to induce 143 
extracellular matrix formation in C28/I2 chondrocytes in which activation of canonical WNT 144 
signaling was achieved directly in the nucleus by overexpressing a constitutively active form of 145 
LEF1 (caLEF1) composed of the transactivation domain of VP16 and the DNA-binding domain 146 
of LEF1 (35) (Fig. 2G). Therefore, the capacity of agrin to suppress canonical WNT signaling is 147 
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essential to its chondrogenic effect. Taken together, these data indicate that agrin induces 148 
chondrogenesis by suppressing canonical WNT signaling. 149 
To test at what level in the signaling cascade agrininhibits WNTs, we activated WNT signaling in 150 
COS7 cells using either the GSK-3β inhibitor BIO (36) or the inhibitor of AXIN/GSK3-β 151 
interaction SKL2001 (37). Disruption of the β-catenin destruction complex with either compound 152 
resulted in ligand/receptor-independent activation of the TOPFlash reporter assay; however, agrin 153 
overexpression was still able to inhibit such activation (Fig 3, A and B), thereby demonstrating 154 
that the capacity of  agrin to inhibit canonical WNT signaling resides downstream of the β-catenin 155 
destruction complex. Similarly, agrin inhibited the activation of the TOPFlash reporter assay 156 
induced by overexpression of constitutively active β-catenin [CTNNB1(Δex3), caCTNNB1] (38) 157 
(Fig 3C). In keeping with the notion that agrin acts downstream of the β-CATENIN destruction 158 
complex, agrin enhanced extracellular matrix production in C28/I2 chondrocytes even in the 159 
presence of SKL2001 (fig. S2). However, when COS7 cells were transfected with caLEF1, Agrin 160 
was unable to prevent activation of the TOPFlash reporter (Fig.3D). Taken together, these data 161 
suggest that agrin suppresses canonical WNT signaling downstream of β-catenin.  162 
 163 
Agrin activates CREB signaling 164 
Agrin was previously reported to activate the Calcium/CaMKII/CREB signaling pathway in 165 
neurons (39–41). We therefore hypothesized that agrin might be blocking canonical WNT 166 
signaling downstream of β-catenin by activating the CaMKII/CREB pathway (21). Agrin 167 
transfection or exogenous recombinant agrin resulted in phosphorylation and consequent 168 
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activation of CREB (pCREB) in C28/I2 chondrocytes (Fig. 3, E to H and fig. S3) and activation 169 
of a CREB reporter assay (42) (Fig 3I). Conversely, silencing endogenous AGRN in C28/I2 cells 170 
using siRNA resulted in a decrease in the number of phosphorylated CREB-positive cells, while 171 
total CREB-positive cells remained unchanged (Fig. 3, J to L). 172 
In the presence of the CREB inhibitor 666-15 (43), agrin failed to suppress the capacity of WNT3A 173 
to activate the TOPFlash reporter assay (Fig 4A), suggesting that the capacity of agrin  to inhibit 174 
WNT signaling is mediated by CREB. Confirming the epistasis of CaMKII in the CREB activation 175 
cascade (39, 40), the CaMKII inhibitors KN93 and AIP negated the capacity of agrin to suppress 176 
the activation of the TOPFlash reporter assay induced by WNT3A when compared to KN92 177 
(inactive control) or vehicle control respectively (Fig. 4B andC). Several signaling pathways 178 
converge onto the CREB pathway with distinct, context-dependent transcriptional and biological 179 
outcomes (44–47). Therefore, we investigated whether the capacity to suppress canonical WNT 180 
signaling is specific to agrin or is a general effect of CREB activation. Forskolin, an activator of 181 
adenyl cyclase and CREB agonist, failed to inhibit activation of the TOPFlash reporter assay after 182 
WNT3A treatment (Fig. 4D). Therefore, CREB activation is required but not per se sufficient for 183 
the capacity of agrin to suppress WNT signaling. We next tested whether agrin-induced CREB 184 
activation is essential for its chondrogenic capacity. In keeping with this hypothesis, agrin or LRP4 185 
lost the capacity to enhance extracellular matrix formation in C28I/2 chondrocytes in the presence 186 
of the CREB inhibitor 666-15 (Fig. 4E to H). Taken together, these data demonstrate that agrin 187 
activates the CaMKII/CREB cascade and that these events are essential for its capacity to inhibit 188 




Agrin supports the repair of critical size osteochondral joint surface defects in mice.  191 
To test if exogenous agrin is sufficient to improve the outcome of joint surface repair in vivo, we 192 
generated cylindrical osteochondral defects in the lateral femoral condyle of adult mice. Defects 193 
were 0.78±0.042 mm wide and 1.79±0.056 mm deep (mean±SD) and extended into the 194 
subchondral spongiosa. Without treatment, such defects result in partial healing of the bone, but 195 
not of the articular cartilage or the subchondral plate, after 8 weeks (fig. S4A-B). A type I collagen 196 
gel containing either human full-length agrin or GFP as control was injected into the joint surface 197 
defect immediately after it was generated. Eight weeks after surgery, the cartilage layer 198 
regenerated significantly  better in the agrin group (Fig. 5A) both in terms of glycosaminoglycan 199 
content (48) (P=0.04141) (Fig. 5B) and Pineda injury score (49) (P=0.04083) (Fig. 5C). The size 200 
of the residual bone defect was also reduced in the agrin group (Fig. 5D), however no evidence of 201 
ectopic bone formation was observed by µCT (fig. S4C). Whereas in the agrin group most of the 202 
repair tissue was composed of either bone or cartilage, in the GFP group there was a larger amount 203 
of non-differentiated fibroblast-like mesenchyme (Fig. 5E). 204 
 205 
Agrin induces GDF5 upregulation in a CREB-dependent manner 206 
We previously reported that the cells that contribute to the repair of cartilage defects derive from 207 
a lineage of progenitor cells that, during skeletal development, express the joint interzone marker 208 
GDF5 (5). During skeletal development, WNT9A induces the expression of GDF5 in the 209 
mesenchymal cells residing in the portion of the skeletal elements that will give rise to the articular 210 
cartilage, menisci, and ligaments, and that are resistant to endochondral bone formation (7, 11, 211 
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13). In adulthood, joint-specific progenitor cells derived from the GDF5 lineage persist within the 212 
synovial membrane and are the main contributors to the regeneration of cartilage defects, which, 213 
when small in size, repair spontaneously (5, 9). Unstimulated human SM-MSCs did not express 214 
detectable GDF5, however, 24 hr after agrin transfection, many of the cells highly expressed GDF5 215 
(Fig. 6A). In addition, agrin transfection induced GDF5 upregulation in C28/I2 human 216 
chondrocytes at protein (Fig. 6B-C) and mRNA levels (Fig. 6D). Conversely, silencing of 217 
endogenous AGRN using siRNA in C28/I2 cells resulted in a reduction of GDF5 expression at 218 
protein (Fig. 6 E and F) and mRNA levels (Fig. 6G). This loss of GDF5 was rescued with the 219 
addition of exogenous rAgrin (Fig. 6E and F). Strikingly, agrin was unable to induce GDF5 220 
expression in bone marrow-derived MSCs (fig. S5). This suggests that the capacity of agrin to 221 
induce GDF5 is restricted to cells of the GDF5-derived lineage, such as chondrocytes and synovial 222 
membrane-derived MSCs (5, 12, 14).  223 
During embryonic development, WNT9A is sufficient to induce GDF5 expression in the joint 224 
interzones. Agrin and WNT9A alone or in combination induced GDF5 protein expression (Fig. 225 
6H to I) and activated the CREB reporter assay (Fig 6J). Interestingly, agrin and WNT9A in 226 
combination induced activation of the CREB reporter assay more than agrin or WNT9A alone. 227 
The CREB inhibitor 666-15 negated the capacity of agrin to induce GDF5 mRNA upregulation in 228 
C28/I2 cells (Fig. 6K), suggesting that the capacity of agrin to upregulate GDF5 is CREB-229 
dependent. Finally, overexpression of constitutively active LEF1, but not WNT3A, also negated 230 
agrin-induced GDF5 upregulation (Fig. 6L to M). This does not necessarily mean that suppression 231 
of WNT signaling drives activation of GDF5, because caLEF1 overexpression also suppressed the 232 
capacity of agrin to induce CREB phosphorylation. Taken together, these results indicate that agrin 233 
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activates GDF5 expression and prompts chondrogenesis through activation of CREB-dependent 234 
transcription and suppression of canonical WNT signaling. 235 
 236 
Agrin induces local accumulation of Gdf5-lineage joint stem cells and phosphorylation of 237 
CREB in vivo 238 
To study whether the Gdf5-lineage of joint-specific MSCs contribute to agrin induced joint surface 239 
repair, we used transgenic mice harboring a tdTomato (Tom) cassette preceded by a LoxP-flanked 240 
stop cassette within the ROSA26 locus and Cre recombinase under the control of the Gdf5 241 
responsive elements active during embryonic development (5, 50). In these Gdf5-Cre;Tom reporter 242 
mice, the progeny of cells that at any point during embryonic development have expressed Gdf5 243 
will express Tom, regardless of whether they still express Gdf5. Similar to our findings in wild 244 
type mice, agrin enhanced joint surface regeneration in Gdf5-Cre;Tom reporter mice (Fig 7A). 245 
Three weeks after surgery there was a marked increase in the number of Tom+ cells within the 246 
superficial portion of the repair tissue as well as in the synovial membrane of the mice that received 247 
agrin compared to controls (Fig. 7B to D). Co-immunofluorescence staining for Tom and collagen 248 
type II at eight weeks after injury revealed the presence of Tom+ chondrocytes embedded in a 249 
collagen type II-containing matrix along the joint surface of the repair tissue (Fig. 7E). 250 
In keeping with our in vitro data, three weeks after surgery we detected a higher percentage of 251 
cells positive for pCREB within the repair tissue of agrin-treated animals (Fig. 7F and G). Dose 252 
response experiments using recombinant agrin revealed that concentrations between 1 and 1000 253 
ng/ml suppressed WNT signaling and activated CREB signaling to a similar extent as COS7-254 
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AGRIN cell lysates (fig. S6A and B). An injection of a collagen gel containing 100 ng/ml rAGRIN 255 
into osteochondral defects also led to increased Tom+ cells in the repair mesenchyme three weeks 256 
after surgery compared to PBS control (fig. S6, C to E), as observed with the COS7-AGRIN cell 257 
lysates.  258 
 259 
Intra-articular agrin delivery improves long-term repair of critical size osteochondral 260 
defects and improves joint function in sheep.  261 
Finally, we tested whether agrin could also support long-term cartilage repair in a large animal 262 
model. A critical-size osteochondral defect (8mm diameter and 5mm deep) was generated in the 263 
weight-bearing region of the medial femoral condyle of adult sheep. The defect was filled with a 264 
type I collagen gel containing either human full-length agrin or GFP as control. At 6 months post-265 
surgery, µCT analysis revealed that bone repair was better in the agrin than the control group, as 266 
noted by reduced defect volume (Fig. 8A and B). The Pineda injury score revealed superior healing 267 
of the defect in the agrin group (Fig. 8C and D). Sheep that received the agrin-containing gel spent 268 
more time playing and less time resting throughout the study (Fig. 8E and F), suggesting that the 269 




We demonstrated that joint surface injury triggers expression of agrin, which in turn recruits 272 
chondrogenic GDF5 lineage joint-resident progenitor cells to the repair mesenchyme and enables 273 
the morphogenesis of joint surface. In critical size defects, which do not heal spontaneously, 274 
exogenous agrin induced GDF5 expression in joint-resident MSCs and triggered their 275 
chondrocytic differentiation by inhibiting WNT signaling downstream of β-catenin in a CREB-276 
dependent manner (fig. S7). Tissue patterning requires temporal and spatial coordination of cell 277 
migration, proliferation and differentiation (6, 10). The WNT, BMP and CREB-dependent 278 
signaling pathways are key players in the patterning and morphogenesis of synovial joints(6, 51) 279 
during embryonic development. Whereas the modulation of these pathways individually failed to 280 
result in morphogenesis  -- for instance, BMP2 is chondrogenic but leads to ectopic cartilage and 281 
bone formation(52) -- exogenous agrin resulted in harmonious postnatal repair morphogenesis.  282 
During embryonic development WNT9A is sufficient (11) but not required (53) to induce joint 283 
formation whereas GDF5 is required (at least for some joints) but not sufficient (13, 54), because 284 
disruption of Gdf5 in mice is not associated with joint fusion. It was previously thought that the 285 
GDF5 lineage of progenitor cells was established early in development and that cells later migrated 286 
to the joint interzones, thereby contributing to the formation of the articular cartilage and ligaments 287 
(12, 14). This concept was challenged by subsequent lineage-tracking experiments using an 288 
inducible system allowing genetic labeling of Gdf5-positive cells at different stages of 289 
development (7). Such experiments demonstrated a continuous recruitment of Gdf5-lineage cells 290 
to the joint interzones throughout development. Cells entering the Gdf5 lineage at different 291 
developmental stages contributed to different tissue structures within the joints. This new paradigm 292 
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is in keeping with our data showing recruitment of Gdf5-lineage cells to the site of injury induced 293 
by agrin even in adulthood. Agrin failed to induce GDF5 in bone marrow-derived MSCs, thereby 294 
suggesting that its function is specific to GDF5-lineage cells. This may explain why agrin, as 295 
opposed to other chondrogenic molecules such as BMPs and TGF-β (55, 56), did not induce 296 
ectopic cartilage or bone formation. 297 
Although both WNT9A and agrin induced GDF5 upregulation, the former is an activator of the 298 
canonical WNT signaling and inhibits chondrogenesis whereas the latter is an inhibitor of 299 
canonical WNT signaling and promotes chondrogenesis. WNT9A enhanced the capacity of agrin 300 
in activating CREB in HEK293 cells. The presence of a cAMP response element (CRE) in the 301 
GDF5 promoter (47) suggests that CREB is a critical element for the capacity of agrin to 302 
upregulate GDF5. 303 
Agrin inhibited canonical WNT signaling downstream of β-catenin. Such mechanism is 304 
independent of the ligands moiety and the WNT receptor repertoire and therefore overrides all 305 
other upstream regulation including activating mutations of β-catenin which result in cancer (57). 306 
This property of agrin may open therapeutic opportunities for its use in other conditions such as 307 
osteoarthritis (58) and cancer (57), in which downregulation of canonical WNT signaling is 308 
desirable without incurring compensatory mechanisms. Notably, WNT inhibition is currently 309 
being tested as a treatment for osteoarthritis (59–62). 310 
The capacity of agrin to induce long-term cartilage regeneration after a single administration 311 
makes it an excellent candidate for clinical use. One problem in clinical translation is 312 
manufacturing. In its fully glycosylated state, agrin is a large, poorly soluble molecule of ~500-313 
600kD which is difficult to purify to clinical grade in a biologically active form. We have shown 314 
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that a purified C-terminal deletion mutant of only ~95kD is sufficient to induce chondrogenesis in 315 
vitro at least as potently as the full-length molecule, but the efficacy of such deletion needs to be 316 
confirmed in vivo, since the N-terminus contains domains responsible for binding to the 317 
extracellular matrix. Such domains, and the capacity of agrin to bind to the extracellular matrix, 318 
may be responsible for its remarkable long-term efficacy.  319 
Another limitation of our study is that we applied agrin therapeutically shortly after surgical 320 
generation of osteochondral defects in otherwise normal knees. In human patients, cartilage defects 321 
are often associated with meniscal/ligament damage and sometimes with some degree of 322 
osteoarthritis. It is still to be proven whether agrin will be able to induce cartilage regeneration 323 
under these circumstances in which joint instability might be compromised, or in the presence of 324 
inflammation. Finally, accurate pharmacokinetic studies and dose responses will be needed to 325 
identify the optimal administration regimen.  326 
No ectopic cartilage was observed after intraarticular delivery despite the chondrogenic capacity 327 
of agrin. This is in contrast with the abundant ectopic cartilage and bone formation observed after 328 
delivery of TGF-β or BMP2 (56, 63). In addition, the chondrogenic and anabolic capacity of agrin 329 
could be detected consistently even in the presence of 10% fetal bovine serum, which overrides 330 
the anabolic capacity of TGF-β and BMPs (64, 65). The capacity of agrin to preserve the 331 
architecture of the native tissue is distinct and of important translational relevance. We anticipate 332 
that the optimization of delivery will be key for the clinical translation in cartilage repair strategies. 333 
  334 
19 
 
Materials and Methods 335 
Study design 336 
The overall scope of this controlled laboratory study was to assess the effect of agrin in the 337 
regeneration of osteochondral defects and its mechanism of action. Human primary cells were 338 
obtained from patients undergoing joint replacement as described below according to ethics 339 
approval REC N. 07/Q0605/29. Cell lines were acquired commercially. Treatments, for each 340 
experiment, are detailed in the figure legends. Sample size of in vitro and in vivo experiments was 341 
determined by power calculations based on previous similar experiments to ensure a power of at 342 
least 0.8 in detecting an effect size of 0.5.  343 
In vivo studies. 344 
Preliminary efficacy study in Fig 5. 345 
Wild type, 10 week old male C57BL/6 mice (4 animals per group, 4 joints analysed) were 346 
subjected to the generation of osteochondral defects as described below and the defect was filled 347 
immediately with  either a collagen gel containing GFP (crude cell extract from transduced COS7 348 
cells) or a collagen gel containing full length agrin (crude cell extract from transduced COS7 cells). 349 
The animals were killed 8 weeks after surgery. 350 
Efficacy study in figure 7.  351 
Female Gdf5-Cre;Tom reporter mice (age 10 week old, 8 mice per group) were subjected to the 352 
generation of bilateral osteochondral defects. The defects were filled immediately with either a  353 
collagen gel containing GFP (crude cell extract from transduced COS7 cells) or a collagen gel 354 
20 
 
containing full length agrin (crude cell extract from transduced COS7 cells). Three mice per group 355 
were killed 3 weeks after surgery and 5 mice per treatment group were killed after 8 weeks. One 356 
joint from the control group at 8 week time point was excluded from analysis because of an 357 
accidental cortical fracture during surgery. 358 
Confirmation of recruitment of Gdf5-Tom+ cells using recombinant agrin (fig S6). 359 
Eight Gdf5-Cre;Tom mice (2 females and 6 males; 3 males and 1female per treatment group) were 360 
subjected to the  generation of bilateral osteochondral defects. The defects were filled immediately 361 
with either a collagen gel or a collagen gel containing 100 ng/ml of recombinant C-terminal agrin 362 
(rAGRIN). Animals were killed after 3 weeks and one joint per animal was processed for analysis. 363 
Efficacy study in sheep (Fig. 8).  364 
Twelve female sheep aged 2.9 years ± 0.41 (SD)were subjected to the generation of an 365 
osteochondral defect. The defects were filled immediately with either a  collagen gel containing 366 
GFP (crude cell extract from transduced COS7 cells) or a collagen gel containing full length agrin 367 
(crude cell extract from transduced COS7 cells). In the GFP group 2 animals were excluded from 368 
the histological analysis, one because of osteomyelitis and one because of a subchondral cyst.  All 369 
animals were killed 6 months after surgery. 370 
In all animal studies, neither the operator nor the assessors were aware of the treatment. To 371 
minimize the risk that fights within individual cages skewed biased the results, treatment was 372 
randomized in each cage in the experiment with wild type mice. All sheep were kept in the same 373 
flock. The treatment table and the outcome tables were kept in separate databases until the 374 
outcomes had been recorded and only merged at the time of statistical analysis.  Conditions to stop 375 
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collection of data and humane endpoints for mice included weight loss >15% or evidence of 376 
excoriating dermatitis for more than 1 week or of ulcerative dermatitis for any length but were 377 
never met. No mouse, therefore, was killed early or excluded from analysis. Three sheep developed 378 
large subchondral cysts as a complication of surgery, which were detected radiographically and 379 
were excluded from further analysis.   380 
 381 
Cells, cell lines and expression vectors 382 
Adult human articular cartilage and synovial membrane were obtained following informed consent 383 
from patients who underwent joint replacement for knee OA after obtaining informed consent (5 384 
men and 3 women, with a mean ± SD age of 68 ± 7 years). All procedures were approved by the 385 
East London and The City Research Ethics Committee 3 (ethics approval REC N. 07/Q0605/29).  386 
Articular chondrocytes and synovial membrane mesenchymal stem cells were isolated and 387 
expanded as previously described (25, 31). Bovine chondrocytes were isolated from the metatarsal 388 
joints of 18-month-old bovine, obtained within 6hrs of death from a local abattoir, as previously 389 
described (25), chondrocytes from three joints were pooled. C28/I2 chondrocytes (66) were a kind 390 
gift from Dr Mary Goldring (HSS Research Institute, Hospital for Special Surgery, New York, 391 
New York). COS-7 cells were a kind gift from Dr Michael Ferns (UC Davis Health system, USA). 392 
HEK293 cells were purchased from ATCC.  393 
All cells were cultured in complete medium (DMEM/F-12, containing 10% FBS and 1% antibiotic 394 
antimycotic solution) (Thermo Fisher Scientific). COS-7 feeders producing agrin or GFP or TGF-395 
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β were obtained as previously described (25). Transfections were performed using JetPrime 396 
(Polyplus) according to the manufacturer’s instructions.   397 
With all cells, chondrogenesis was assessed in micromass culture as previously described (25, 48, 398 
67). Extracellular matrix deposition was quantified by staining with Alcian Blue 8 GS (Merck) at 399 
pH 0.2 followed by extraction in 8 M guanidine HCl (Thermo Fisher Scientific) and 400 
spectrophotometric quantitation at a wavelength of 630nm (25, 48, 67). DNA was quantified using 401 
the Sybr Green method according to manufacturer’s instruction (Origene). 402 
The Rat Agrin plasmid (68) was a kind gift from Dr Michael Ferns (UC Davis Health system, 403 
USA). The Lrp4 plasmid (23) was a kind gift of Dr Lin Mei (Medical College of Georgia, Augusta, 404 
USA). TGF-β plasmid was a kind gift from Dr. Gerhard Gross. The caLEF1 and the caCTNNB1 405 
plasmids were a kind gift from Dr. Carles Gasson-Massuet.  406 
siRNA oligonucleotide sequences can be found in table S1. A Stealth RNAi negative control 407 
duplex of low guanine-cytosine (GC) content (Invitrogen) was used as a negative control for 408 
AGRN siRNA. 409 
 410 
Generation of agrin-expressing COS7 cells and agrin-containing collagen gel 411 
The full-length coding sequence of human agrin (accession N. AB191264) was cloned into the 412 
BamHI and Kpn1 site of the pLNTSFFV. The agrin sequence was synthesized in 3 parts by Gene-413 
Art (Life Technologies). The 5’ fragment was ligated into the BamHI/XhoI sites of the vector. The 414 
3’ fragment was the ligated into this plasmid at the XhoI and Kpn1 sites. Finally, the Xho1 415 
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fragment comprising the central portion of the gene was ligated into the XhoI site of the vector to 416 
give the complete cDNA. Lentiviruses were packaged in HEK 293T cells using standard 417 
procedures. The agrin lentivirus (or GFP lentivirus as control) was used to transduce COS7 cells, 418 
which were then cloned by limiting dilution. After three passages, the clone with the highest 419 
expression of agrin as determined by immunofluorescence was selected and used for further 420 
studies.  421 
To generate collagen gel containing agrin (or GFP as control), agrin or GFP-overexpressing COS7 422 
cells were washed twice in ice-cold PBS, detached mechanically with a cell scraper, resuspended 423 
in PBS, pelleted at 10000 g for 20 minutes and resuspended in an equal volume of PBS. The 424 
samples were subjected to 5 cycles of freeze-thawing alternating between liquid nitrogen and a 425 
37°C water bath and finally diluted 1:1 in a 5 mg/ml solution of ice-cold type I rat tail collagen at 426 
pH 7.5 (Corning - 354249) prepared according to the manufacturer’s instruction. The preparation 427 
was kept on ice to prevent polymerization until injected. 428 
 429 
Generation of recombinant Agrin 430 
Recombinant human non-neuronal C-terminal Agrin (rAGRIN) was generated as follows. The C-431 
terminal portion of Agrin (AA 1244-2045 from GeneBank accession number BAD52440) was 432 
cloned by PCR from the backbone of the full-length human non-neuronal Agrin adenovirus and 433 
subcloned into a 3rd generation lentivirus gene expression vector backbone downstream of the 434 
CMV promoter, an IgG kappa signal peptide and followed by an enterokinase cleavage site, 435 
thermostable alkaline phosphatase, Myc and 10X His tags and finally by a stop codon. The 436 
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lentivirus backbone was transiently transfected into Expi293 cells (Thermo Fisher Scientific) using 437 
the Expi293 Expression System (Thermo Fisher Scientific) as per manufacturer’s instructions. At 438 
day 3 post transfection, cell-free supernatant was collected and recombinant Agrin was recovered 439 
using His SpinTrap columns (GE Healthcare), according to manufacturer’s instructions. 440 
 441 
Animals and animal procedures 442 
All animal procedures were subjected to local ethical approval and Home Office Licensing. Mouse 443 
experiments were regulated by PPL no. 70/7986 and 60/4528, sheep experiments by PPL no. 444 
70/7740. C57BL/6 mice were purchased from Charles River UK. Gdf5-Cre;Tom mice (5) were 445 
generated by crossing Gdf5-Cre transgenics (Tg(Gdf5-Cre-ALPP)1Kng) (14) (Kind gift of Dr D. 446 
Kingsley, Stanford, CA, USA) with Cre-inducible tdTomato (Tom) reporter mice (B6.Cg-447 
Gt(ROSA) 26Sortm14(CAG-tdTomato)Hze/J) (Jackson Laboratories). Gdf5-Cre;Tom mice were 448 
on a mixed FVB/C57BL/6 background. All mice were maintained in isolator cages or standard 449 
housing in groups of 3-5 and fed ad libitum.  450 
 451 
Murine model of osteochondral defect repair 452 
Mice were anesthetized with isofluorane. The knees were shaved and disinfected with 70% 453 
ethanol. The skin was cut with fine scissors and separated from the underlying tissue by blunt 454 
dissection. The femur was placed so that the shaft was perfectly vertical, with the knee flexed at 455 
90°. A 25G needle (Terumo Agani G25, cannula 0.5mm, length 25mm, bevel 11°) was placed on 456 
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the lateral condyle in correspondence of the intersection of a vertical line tangent to the lateral 457 
margin of the patella and a horizontal line tangent to the inferior margin of the patella. By applying 458 
gentle pressure and rotation, the needle was driven through the joint capsule, the cartilage, and the 459 
bone, while aiming for the center of the femoral shaft. As soon as the bevel of the needle was 460 
completely buried, the G25 needle was retracted and replaced with a G21 needle (Terumo Agani, 461 
G21, cannula 0.8 mm, length 50 mm, bevel 11°). The G21 needle was again gently rotated and 462 
advanced until its bevel was completely hidden. The G21 was retracted while still turning to extract 463 
the bone debris and leaving a cavity. If there was any bleeding, this was blotted with sterile gauze. 464 
Liquid collagen type I gel containing the lysate of COS7 cells overexpressing full-length human 465 
agrin(crude extract from transduced COS7 cells)accession No. AB191264) or recombinant C-466 
terminal agrin as indicated, or GFP (crude extract from transduced COS7 cells) or PBS as 467 
indicated, was injected using a pulled glass pipette tip with a diameter of approximately 10µm 468 
mounted at the end of a regular 2 µl pipette tip until the defect was full. After waiting 469 
approximately 20 seconds to allow the gel to set, the joint capsule was closed with a single suture 470 
with Vycril 6-0 and the skin was closed with an interrupted suture (Ethilon 5-0 a-traumatic needle). 471 
After recovery mice, fed ad libitum in individually filtered cages (3-5 mice per cage). For wildtype 472 
mice, treatments were randomized within each cage. The animals were monitored post-operatively 473 
for signs of suffering and local infection. The operator and the scorers were blind to the treatment.  474 
At the stated time points mice were killed, the joint dissected and processed for histology. Sagittal 475 
sections through the center of the defect were identified as the first section that, starting from the 476 
lateral side, intersected the lateral margin of the patellar bone. Such sections were stained with 477 




Ovine model of osteochondral defect repair 480 
Adult [aged 2.9 years ± 0.41 (SD); individual ages can be found in table S1] female sheep were 481 
anesthetized with isoflurane. Following a sterile preparation of the skin, the joint was opened using 482 
a lateral para-patella approach. An 8 mm diameter, 5 mm deep osteochondral defect was created 483 
using a hand drill. The defect was lavaged to remove debris. Defects were filled with liquid 484 
collagen type I gel containing the lysate of COS7 cells overexpressing full length human agrin or 485 
GFP as control. After waiting about 20 seconds to allow the gel to set, the capsule was closed using 486 
3M Monocryl in an interrupted mattress pattern. The skin was closed with 2M Vicryl. Sheep were 487 
recovered and then housed for two weeks post-surgery indoors in pens. Carprofen was 488 
administered at a dose of 4 mg/kg at the time of surgery then 4 mg/kg once a day for three days 489 
post-surgery. After this time, sheep were kept in one flock in a field to allow free and natural 490 
movement. At 6 months post-surgery sheep were killed, the knees processed for µCT and 491 
subsequently processed for histology. Mid-defect sections were stained and scored as described 492 
above. 493 
For µCT analysis, sheep knee joints were scanned using a Nikon XT H 225 ST CT scanner. 494 
Reconstruction was done using CT Pro V2.2 Nikon software (Nikon Metrology UK Ltd) and the 495 
images were saved as a tif series. These were then viewed using Dataviewer v1.5 software (Bruker, 496 
Kontich). To allow subsequent analysis the data was then resaved as a transaxial (x,y) dataset. This 497 
new dataset was then opened in CTAn (v1.13) (Bruker, Kontich).  Before analysis was carried out 498 
the true pixel value from the Nikon scan was manually added using the image properties option, 499 
as the calibration was not automatically saved. A region of interest was drawn to define the defect 500 
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area in each joint, from which the defect volume was determined. The person analyzing the µCT 501 
data was blinded to the study groups. 502 
 503 
Histology and immunostainings 504 
All samples were fixed in 4% paraformaldehyde at 4°C overnight, decalcified in 10% EDTA in 505 
PBS for 2 weeks at 4°C (Gdf5-Cre;Tom) or in 33% Formic Acid for 24hrs and then washed for 506 
24hrs in water at room temperate (wildtype), dehydrated in an ethanol series, embedded in paraffin 507 
and 5 µm sections were obtained. Safranin O staining (pH 4.2) or toluidine blue (pH 4.5) was 508 
performed according to standard protocols.  509 
Immunofluorescence and immunohistochemical, staining was carried out as previously described 510 
(25, 48). For antigen retrieval on paraffin sections pepsin digestion was performed. Where 511 
phosphatase treatment was carried out, sections were incubated with Lambda phosphatase for 2hrs 512 
at 37°C according to manufacturer’s instructions (CST). Antibodies and dilutions used are 513 
provided in table S2. Tissue staining was carried out using an overnight incubation of the primary 514 
antibody at 4°C, immunocytochemistry was performed following 1hr incubation at room 515 
temperature. Sections were counterstained with hematoxylin or with 4′,6-diamidino-2-516 
phenylindole (DAPI) (Life Technologies). Slides were mounted in Mowiol (EMD Millipore, 517 
Darmstadt), and images were acquired with a fluorescence microscope (BX61; Olympus) using a 518 
Uplan-Fluor 40× NA 0.85 objective lens, a Zeiss 710 META Laser-Scanning Confocal 519 
Microscope (Carl Zeiss Ltd), or a Zeiss Axioscan Z1 slide scanner (Carl Zeiss Ltd). Images were 520 
acquired by using an F-View II Soft Imaging Solutions (SIS) camera and Cell P software 521 
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(Olympus), or using ZEN software (Carl Zeiss Ltd). Image contrast was modified with Photoshop 522 
7.0 for best graphic rendering, equally for all treatments. 523 
 524 
Histomorphometry 525 
Histomorphometry was performed with ImageJ software (NIH). The number of cells positive for 526 
phospho-CREB (pCREB) was calculated as follows. Images of immunohistochemistry 527 
counterstained with hematoxylin were opened in ImageJ (69). All cells (positive and negative) 528 
were selected using the color threshold tool (Image>Adjust>Color threshold). The tool was set on 529 
the RGB color space and all three (red, blue and green) channels were passed, ensuring that the 530 
blue channel (hematoxylin positive cells) was passed with the upper limit on the peak of the 531 
histogram. The passed component of the image was sampled and pasted on a new image. Such 532 
image contained all cells, positive (brown) and negative (blue) and no background. This image 533 
was converted to 8 bit and thresholded in such a way to maximize separation of adjacent cells 534 
while still selecting every cell. A further deconvolution of overlapping cells was obtained using 535 
the watershed tool (Process>binary>watershed). Total cells were then counted with the Analyze 536 
Particles tool (Analyze>Analyze Particles). Care was taken to optimize the size of the particles to 537 
count so to exclude specks that did not reach the minimum size of a cell. In our case we used 100 538 
px~infinity. The positive cells were counted in the same way except that during colour 539 
thresholding, the upper limit of the blue channel was placed immediately to the left of the blue 540 
histogram, so that all blue cells were thresholded out and the resulting image only contained brown 541 
cells. The counts were expressed as (positive/total cells) x100. 542 
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The number of cells positive for Tomato in immunohistochemistry could not be quantified in the 543 
same way because the cytoplasmic staining of neighboring cells could not always reliably be 544 
deconvoluted. Therefore, the area occupied by brown (immunohistochemistry) or blue 545 
(hematoxylin) staining was considered as proportional to the positive and negative cells. Image 546 
processing for this analysis was similar to that described above for phospho-CREB staining, with 547 
the following differences. First, after color thresholding, the second round of thresholding was 548 
performed so to include the entire histogram of the 8-bit images so not to alter the area occupied 549 
by any positive staining in the 8-bit images. Second, instead of the particle count, we used the 550 
“total area” of the results from “Analyze Particles” as (total area total cells/total area positive 551 
cells) x100. 552 
Western blotting 553 
Cells were washed in ice-cold PBS and lysed in ice-cold RIPA Buffer in the presence of protease 554 
and phosphatase inhibitors (Sigma) for 20 mins on ice. Protein concentrations were determined by 555 
bicinchoninic acid protein assay (Pierce). Samples were prepared for SDS-PAGE on 10% (wt/vol) 556 
Bis-Tris NuPAGE gels (Invitrogen) and transferred to nitrocellulose membrane. Blots were 557 
blocked in 5% BSA in 0.1% TBS-Tween) and incubated with primary antibodies at the 558 
concentrations stated in supplementary table I overnight at 4°C. After three washes in 0.1% TBST, 559 
blots were incubated for one hour at room temperature with HRP-conjugated secondary IgG 560 
(Dako). After further three washes, protein bands were visualized by chemiluminescence 561 
(Luminata Forte; Merk Millipore) using FluorChem E imaging system (Protein Simple). 562 
Measurements of band densitometry and quantification of protein expression was conducted using 563 
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ImageJ (NIH) (69). Phospho protein expression was normalized to total protein levels and to α-564 
TUBULIN (endogenous loading control). 565 
 566 
Reporter assays 567 
Subconfluent cells were co-transfected with SUPER8XTOPFlash (34) TCF/LEF–firefly luciferase 568 
reporter vector (Addgene) and CMV-Renilla luciferase vector (in a ratio 1:100). 24hrs after 569 
transfection, the medium was replaced and the cells were treated for 24hrs as specified. Luciferase 570 
activity was measured using the Dual Luciferase Reporter Assay System (Promega) in a TD-20/20 571 
Luminometer (Turner Designs). Firefly luciferase activity was normalized by Renilla luciferase 572 
activity and expressed as relative luciferase units. See table S3 for all reagents. 573 
Gene expression analysis 574 
RNA extraction was performed using Trizol (Invitrogen) according to the manufacturer’s 575 
instruction. Reverse transcription and real-time PCR were performed as previously described (25). 576 
Primers and amplicon length are listed in table S4. 577 
Microarray data from previously published datasets (30)  were accessed through the Gene 578 
Expression Omnibus database at NIH (GEO accession GSE75181). Briefly, normalized data were 579 
downloaded from GEO as an expression dataset; the samples of interest (IL-1β-treated and control) 580 
were selected and gene expression was compared by fitting a linear model independently for each 581 
probe, with group as the y variable, using 'lmfit' ('limma' R package).  The linear fit for each 582 
comparison was subsequently modified using the empirical Bayes ('eBayes') approach. For each 583 
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comparison, log2 fold-change (logFC), P value, and adjusted P value (false discovery rate, FDR 584 
for multiple comparisons) was output. Individual samples expression data for agrin were extracted 585 
from the expression dataset and the statistics obtained from the statistics output and used to build 586 
the graph. To facilitate the reproduction of the data, an R script is supplied in supplementary 587 
materials to obtain the raw data, select the samples of interest, perform the statistical analysis and 588 
generate the graph. Pre-processed, normalized data for individual genes were obtained using the 589 
GEO2R functionality. 590 
  591 
Statistical analysis  592 
Means of parametric data were compared with a student’s t test or with ANOVA followed by 593 
Tukey HSD post hoc test for multiple comparisons. When necessary, log or square root 594 
transformation was applied to correct skewed distributions in order to satisfy the assumptions of 595 
parametric tests. Non-parametric data were analyzed with the Mann-Whitney U test or, for 596 
multiple comparisons, the Kruskal Wallis test followed by the Dunn test. Dose response curves 597 
and repeated measures were assessed by two-way ANOVA and, if different treatments were 598 
applied, ANCOVA followed by Tukey HSD for multiple comparisons. Statistical analysis was 599 
performed using either R or GraphPad Prism software. Data shown as box and whisker blot. Box 600 
extends from the 25th to 75th percentiles. Error lines represent max to min points. P values 601 
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Fig. 1. Agrin is upregulated after cartilage injury, induces chondrogenesis in MSCs, and is 843 
chondrogenic in joint-resident MSCs. (A) RT-PCR for AGRN of human adult articular cartilage 844 
explants after mechanical injury or in control conditions (n = 7), paired t-test P = 0.0044. Individual 845 
values plotted. (B) AGRIN immunostaining (red) of human adult articular cartilage explants after 846 
mechanical injury or in control conditions; bars 50 µm, counterstained with DAPI (blue). (C) 847 
Quantification of AGRIN staining normalized for number of cells (n = 3), paired t-test P = 0.0222. 848 
Individual values plotted. (D) RT-PCR for AGRN in C28/I2 chondrocytes treated for 3 days with 849 
IL-1β (20 ng/ml, n = 9, t-test P<0.0001) or (E) TNF-α (20 ng/ml, n = 8, t-test P=0.0080). (F) 850 
Alcian blue staining and spectrophotometric quantitation of glycosaminoglycans in micromasses 851 
of SM-MSCs over a feeder of growth-arrested COS7 cells overexpressing AGRIN (n = 8), GFP 852 
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(n = 7), or TGF-β (n = 8) for 6 days, one-way ANOVA with Tukey’s HSD post-hoc GFP vs 853 
AGRIN P<0.0001, GFP vs TGF-β P=0.0028, AGRIN vs TGF-β P<0.0001; bars 0.5mm (G) RT-854 
PCR for SOX9 of SM-MSC micromasses overexpressing AGRIN or GFP (n = 4), t-test P=0.0402. 855 
Box and whiskers plots show all values, boxes extend from the 25th to 75th percentiles, error bars 856 






Fig. 2. Agrin/LRP4 signaling activates chondrogenesis by inhibiting WNT signaling.  859 
(A-C) RT-PCR for SOX9 of primary bovine chondrocytes transfected with (A and C) LRP4 or (B) 860 
AGRIN and treated with (A-B) recombinant WNT3A  or (C) co-transfected with AGRN siRNA (n 861 
= 3, lined bars; n  =4, square bars) ); (A) SOX9 levels were compared using a generalized linear 862 
model followed by pairwise comparison within each WNT3A treatment (Tukey correction), 863 
GFP+Vehicle vs LRP4+vehicle P=0.0198, GFP+WNT3A vs LRP4+WNT3A P=0.0089. (B) 864 
Square root transformed SOX9 levels were compared using a generalized linear model followed 865 
by pairwise comparison within each WNT3A treatment (Tukey correction),  AGRIN+Vehicle vs 866 
GFP+Vehicle P<0.0001,  AGRIN+WNT3A vs GFP+WNT3A P= 0.0278; (C) t-test, 867 
GFP+Scrambled vs LRP4+Scrambled P=0.0157, LRP4+Scrambled vs LRP4+AGRN siRNA 868 
P=0.0107. (D) TOPFlash reporter assay in COS7 cells transduced with AGRIN or GFP and treated 869 
with recombinant WNT3A (100 ng/ml) (n = 4); t-test GFP vehicle vs GFP WNT3A P=0.0001, 870 
GFP WNT3A vs AGRIN WNT3A P=0.0005. (E) TOPFlash reporter assay in HEK293 cells 871 
transfected with AGRIN or GFP and treated with recombinant WNT9A (200 ng/ml) (n = 3); one 872 
way ANOVA with Tukey  GFP + Vehicle vs GFP+WNT9A P=0.0015, GFP+WNT9A vs 873 
AGRIN+WNT9A p<0.0001. (F) TOPFlash reporter assay of COS7 cells stably expressing AGRIN 874 
or GFP and transfected with either Empty plasmid or LRP4 plasmid and treated with increasing 875 
doses of recombinant WNT3A (n = 4; two-way ANOVA – Tukey HSD. AGRIN vs GFP 876 
P<0.0001; AGRIN+LRP4 vs AGRIN P= 0.027. Mean values with SEM are plotted. (G) Alcian 877 
blue staining and quantification of C28I/2 chondrocytes in micromass culture 4 days after 878 
transfection with AGRIN or GFP with or without caLEF-1 (n = 4) two-way ANOVA P=0.0088; 879 
bars 0.5 mm. Box and whiskers plots show all values, boxes extend from the 25th to 75th 880 









Fig. 3. Agrin inhibits canonical WNT signaling downstream of β-catenin and activates 884 
CREB-dependent transcription.  885 
(A) TOPFlash reporter assay in COS7 cells transduced with AGRIN or GFP treated with BIO, 886 
(GFP+ Vehicle, n = 6, GFP + BIO n = 3, AGRIN+ BIO n =  4), (B) SKL2001, (GFP + Vehicle n 887 
= 8, GFP + SKL2001 n = 4, AGRIN + SKL2001 n = 3), (C) transfected with caCTNNB1(Δex3) 888 
(n = 4) or (D) constitutively active LEF-1 (n = 4); (A to D) one-way ANOVA followed by Tukey’s 889 
HSD post-hoc. (A) Vehicle vs GFP+BIO P=0.0094, GFP+BIO vs AGRIN+BIO P=0.0007, (B) 890 
Vehicle vs GFP+SKL2001 P=0.0028, GFP+SKL2001 vs AGRIN+SKL2001 P=0.0053, (C) 891 
GFP+Empty plasmid vs AGRIN+Empty plasmid P<0.0001, GFP+caCTNNB1 vs 892 
AGRIN+caCTNNB1 P=0.0292, (D) GFP+Empty plasmid vs GFP+caLEF1 P<0.0001. (E) 893 
Immunostaining for CREB or phosphorylated CREB (pCREB) in C28/I2 cells 24 hr after 894 
transfection with AGRIN or GFP (red) with DAPI counterstain (blue). Quantification in (F and G) 895 
(n = 3); (G) t-test P=0.0256. (H) C28/I2 chondrocytes were cultured for 3 days in micromass, 896 
transfected as indicated, and CREB phosphorylation (p-CREB) was assessed by western blotting 897 
(n = 3); two-way ANOVA GFP vs AGRIN P=0.0055, AGRIN vs GFP+caLEF1 P=0.008, AGRIN 898 
vs AGRIN+caLEF1 P=0.0035. (I) CREB reporter assay in COS7 cells transfected with AGRIN 899 
(n = 4) or GFP (n = 3); t-test P=0.0462. (J) Immunostaining for CREB and phosphorylated CREB 900 
(pCREB) (red) with DAPI counterstain (blue) in C28/I2 cells 24hr after transfection with 901 
Scrambled or AGRN siRNA and quantification in (K and L) (n = 3); t-test P=0.0021. Box and 902 
whiskers plots show all values, boxes extend from the 25th to 75th percentiles, error bars span max 903 







Figure 4. Agrin requires CREB for its capacity to suppress WNT signaling and induce 907 
chondrogenesis. 908 
(A) TOPFlash reporter assay in COS7 cells transfected with Agrin or GFP 24 hours after treatment 909 
with WNT3A in the presence or the absence of the CREB inhibitor 666-15 (n = 4). (B and C) 910 
TOPFlash reporter assay in COS7 cells transfected with AGRIN or GFP 24 hrs after WNT3A (200 911 
ng/ml) treatment in the presence or in the absence of (B) the CaMKII inhibitor KN93 or its inactive 912 
control KN92 or (C) the CaMKII inhibitor AIP; (A to C) two-way ANOVA Tukey’s HSD post-913 
hoc, (A) Vehicle+GFP vs WNT3a+GFP P<0.00001, WNT3a+GFP vs WNT3a+AGRIN 914 
P=0.0004, WNT3a+AGRIN vs 666-15+WNT3a+AGRIN P=0.0007; (B) KN92+GFP vs 915 
KN92+WNT3A+GFP P<0.00001, KN92+WNT3A+GFP vs KN92+WNT3A+AGRIN P=0.0001, 916 
KN92+WNT3A+AGRIN vs KN93+WNT3A+AGRIN P= 0.0046, KN92+GFP vs 917 
KN93+WNT3A+AGRIN P=0.0025, (C) Vehicle+GFP vs WNT3A+GFP P<0.0001, 918 
Vehicle+GFP vs AIP+WNT3A+AGRIN P<0.0001, WNT3A+GFP vs WNT3A+AGRIN 919 
P<0.0001, WNT3A+AGRIN vs AIP+WNT3A+AGRIN P=0.0019. (D) TOPFlash reporter assay 920 
in COS7 cells transfected with either AGRIN or GFP treated with WNT3A (200 ng/ml) and/or  921 
Forskolin(10 µM); Kruskal-Wallace, overall P=0.0168. Multiple comparison was carried out 922 
using a Dunn test,P values obtained with the Benjamini-Hochberg correction Vehicle vs WNT3A 923 
P=0.0280, WNT3Avs WNT3A+AGRIN P=0.0451, Vehicle vs Forskolin + WNT3A +GFP. (A to 924 
D n = 4). (E) Representative images of Alcian blue staining of C28/I2 chondrocytes in micromass 925 
culture transfected with either empty plasmid or AGRIN and LRP4 in the presence or the absence 926 
of the CREB inhibitor 666-15; bars 0.5 mm. (F to H) Glycosaminoglycans quantification from the 927 
experiment in E (n = 4); log transformed values, one-way ANOVA, Tukey’s HSD post-hoc, (F) 928 
Empty plasmid vs LRP4 P=0.0032, LRP4 vs LRP4+666-15 P=0.0002, (G) Empty plasmid vs 929 
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AGRIN P=0.0023, AGRIN vs AGRIN+666-15 P<0.0001, (H) Empty plasmid vs LRP4+AGRIN 930 
P=0.0094, AGRIN+LRP4 vs AGRIN+LRP4+666-15 P=0.0027. Box and whiskers plots show all 931 
values, boxes extend from the 25th to 75th percentiles, error bars span max to min values.  932 
 933 
 934 
Fig. 5. Agrin supports repair morphogenesis and articular cartilage formation in vivo.  935 
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(A) Representative safranin O staining of the femoral condyle of C57BL/6 mice 8 weeks after the 936 
generation of an osteochondral defect filled with a collagen gel containing either AGRIN or GFP 937 
(n = 4); bars 200 µm. The dotted lines represent the approximate location of the original defect. M 938 
= meniscus; F = Femur; T = tibia (B) Quantification of Safranin O staining in the repair cartilage 939 
layer (n = 4). T-test after logarithmic transformation P=0.041. (C) Pineda score of osteochondral 940 
defect repair after 8 weeks (lower scores indicate better repair) (n = 4), Mann-Whitney U test, 941 
P=0.0140. (D) Histomorphometric quantification of the residual bone defect. (n = 4; Welch Two 942 
Sample t-test following log transformation; P=0.0087). (E) Quantification of the non-943 
differentiated (fibroblast-like) portion of the repair mesenchyme (n = 4; Welch Two Sample t-test 944 
following log transformation; P=0.0021). Box and whiskers plots show all values, boxes extend 945 






Fig. 6. Agrin supports GDF5 expression in synovial membrane MSCs  948 
(A and B) GDF5 immunocytochemistry of SM-MSCs (A) or C28/I2 cells (B) transfected with 949 
AGRIN or GFP (red) and cultured in monolayer for 24 hrs (n = 4); bars 50 µm. DAPI counterstain. 950 
(C) Quantification of GDF5 staining intensity in (B) normalized by number of cells; t-test 951 
P=0.0072. (D) RT-PCR for GDF5 in C28/I2 cells transfected with AGRIN or GFP and cultured 952 
for 3 days in micromass (n = 4); t-test P=0.0148. (E) GDF5 immunocytochemistry (red)  953 
counterstained with DAPI (blue) of C28/I2 cells cultured in monolayer for 24 hrs following 954 
transfection with Scrambled or AGRN siRNA in the presence or absence of rAGRIN; bars 50 µm. 955 
(F) Quantification of % GDF5+ cells from (E) Scrambled n = 3; AGRN siRNA n = 3; AGRN 956 
siRNA+rAGRIN n = 6) one-way ANOVA Scrambled vs AGRN siRNA P=0.0024, AGRN siRNA 957 
vs AGRN siRNA+rAGRIN P=0.024; and mean intensity per cell, one-way ANOVA using 958 
generalized linear model followed by pairwise comparison within each Scrambled vs AGRN 959 
siRNA P=0.0134, AGRN siRNA vs AGRN siRNA+rAGRIN P=0.0455. (G) RT-PCR for GDF5 960 
in C28/I2 cells transfected with Scrambled or AGRN siRNA cultured for 3 days in micromass (n 961 
= 4); t-test P= 0.0358. (H) Immunostaining for GDF5 in C28/I2 chondrocytes treated with 962 
recombinant AGRIN (300 ng/ml) and/or WNT9A (200 ng/ml) for 24 hrs; bars 50 µm; and (I) 963 
quantification (n = 4); after reciprocal transformation values were compared by one-way ANOVA 964 
with Tukey HSD post-hoc for multiple comparisons  P=0.0008; PBS vs WNT9A P=0.0036, PBS 965 
vs rAGRIN P=0.0048, PBS vs WNT9A+AGRIN P=0.0008. (J) CREB reporter assay in HEK293 966 
cells treated with recombinant AGRIN (300 ng/ml)and/or WNT9A (200 ng/ml) (n = 4); one-way 967 
ANOVA with Tukey test for multiple comparisons on log transformed values  P=Vehicle+GFP 968 
vs WNT9A+GFP P=0.0427630, Vehicle+GFP vs Vehicle+AGRIN P=0.0063, Vehicle+GFP vs 969 
WNT9A+AGRIN P<0.0001, Vehicle+AGRIN vs WNT9A+AGRIN P=0.0169, WNT9A+GFP vs 970 
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WNT9A+AGRIN P=0.0025. (K to M) RT-PCR for GDF5 mRNA in C28/I2 cells transfected with 971 
AGRIN or GFP plasmids, cultured in micromass for 4 days and treated in the presence of (K) 666-972 
15 (1 µM) or vehicle or (L) co-transfected with caLEF1 plasmid or (M) recombinant WNT3A 973 
(200 ng/ml) (n = 4); one-way ANOVA with Tukey’s HSD post-hoc (K) GFP vs AGRIN P=0.0111, 974 
AGRIN+vehicle vs AGRIN666-15 P=0.0277, (L) GFP vs AGRIN P=0.0111, AGRIN vs 975 
GFP+caLEF1 P=0.0003, AGRIN vs AGRIN+caLEF1 P=0.00033, (M) AGRIN+vehicle vs 976 
GFP+WNT3A P=0.0230. Box and whiskers plots show all values, boxes extend from the 25th to 977 





Fig. 7. Agrin-induced joint surface repair is associated with increased recruitment of Gdf5-981 
lineage joint stem cells and CREB phosphorylation in the repair mesenchyme.  982 
(A) Pineda score of Gdf5:Tom transgenic mice 8 weeks after the generation of an osteochondral 983 
defect filled with either agrin or GFP (n = 9 GFP, n = 10 AGRIN; Mann-Whitney U test; 984 
P=0.01994). (B) Immunohistochemistry for Tomato in the defect of Gdf5:Tom transgenic mice 3 985 
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weeks after the generation of an osteochondral defect filled with a collagen gel containing either 986 
AGRIN or GFP; sm=synovial membrane; rm=repair mesenchyme (n = 6). Boxed region shown at 987 
higher magnification below; bars 50 µm. (C) Quantification of Tom+ cells in the repair 988 
mesenchyme and (D) in the synovial membrane; t-test (C) P=0.0002, (D) P=0.0398. Box and 989 
whiskers plots show all values, boxes extend from the 25th to 75th percentiles, error bars span max 990 
to min values. (E) Safranin O (left panels) and immunofluorescence (right) for Tomato (red) and 991 
Collagen type 2 (green) 8 weeks post-surgery, counter stained for DAPI (blue). Boxed region 992 
shown at higher magnification below; bars 100 µm. Immunohistochemistry (F) and quantification 993 
(G) of phospho-CREB (pCREB) in the repair mesenchyme of Gdf5;Tom mice treated with AGRIN 994 
or control, 3 weeks after the generation of an osteochondral defect (n = 3); phosphatase treatment 995 
was used as staining control; (F) Welch two sample t-test of squared values P=0.04058; bars 100 996 






Figure 8. A single administration of agrin in critical size joint surface defects in sheep 999 
regenerates the articular cartilage.  1000 
Sheep underwent the generation of an osteochondral defect that was filled with a collagen gel 1001 
containing AGRIN or GFP and killed after 6 months (n = 6). (A) Representative µCT images of 1002 
defects at 6-month time-point (n = 6; scale bar 5mm) and (B) quantification of the residual non-1003 
calcified defect area (n = 6 control and n = 5 Agrin; Welch t-test after log transformation, 1004 
P=0.0134). (C) Safranin O staining of the joint surface defect area, bars 200 µm. (D) Pineda 1005 
score (n = 4 controls and n = 6 AGRIN; Mann-Whitney U test P=0.0333. (E) Time spent playing 1006 
(two-way ANOVA, Treatment P=0.00495) and (F) time spent resting (two-way ANOVA, 1007 
Treatment P=0.00043). (G) AGRIN promotes the morphogenesis of the repair mesenchyme at 1008 
the site of cartilage injury. This process involves the activation of CREB-dependent upregulation 1009 




Supplementary figure 1. (A) Microarray human chondrocytes – (mined from GEO accession 1016 
GSE7518130), P< 0.0001 (n = 12). (B) RT-PCR for DKK1in C28/I2 cells transfected with 1017 
Scrambled or AGRN siRNA cultured for 3 days in micromass (n = 4).  1018 
 1019 
Supplementary figure 2. Alcian blue staining and quantification of C28I/2 chondrocytes in 1020 
micromass culture 4 days after transfection with GFP or AGRIN with or without SKL2001 (n = 1021 
4), two-way ANOVA P=0.0013, GFP + Vehicle vs AGRIN + Vehicle P= 0.0815, GFP + 1022 




Supplementary figure 3. (A) Temporal analysis by western blot of pCREB in C28/I2 cells 1025 
treated with 100 ng/ml rAgrin normalized to (B) CREB and tubulin (one-way ANOVA followed 1026 






Supplementary figure 4. (A) Unoperated joint of a mouse stained with Toludine blue. (B) 1029 
Untreated subchondral defect in mice 8 weeks post-surgery stained with toluidine blue. (C) 1030 
MicroCT of Gdf5-Cre;Tom mice 8 weeks post-surgery. 1031 
 1032 
Supplementary figure 5. Immunofluorescence for GDF5 in murine bone marrow derived stem 1033 
cells treated with rAgrin (100 ng/ml) compared to C28/I2 chondrocytes as positive control; bars 1034 




Supplementary figure 6. (A) TOPFlash reporter assay of HEK293 cells cultured in the presence 1037 
of COS7-AGRIN or COS7-GFP cell lysate (used at ratio equal to in vivo) and compared to 1038 
increasing doses of recombinant Agrin (rAgrin) in the presence of WNT3A (n = 4). (B) CREB 1039 
reporter assay of HEK293 cells cultured in the presence of COS7-AGRIN or COS7-GFP cell 1040 
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lysate (used at ratio equal to in vivo) and compared to increasing doses of recombinant AGRIN 1041 
(rAGRIN), forskolin was used as a positive control (n = 4); (A and B) one-way ANOVA, 1042 
*=p<0.05, **=p<0.01,***=p<0.001, ****=p<0.0001. (C) Immunofluorescence for Tomato in 1043 
the defect of Gdf5:Tom transgenic mice 3 weeks after the generation of a joint surface defect 1044 
filled with a collagen gel containing either rAGRIN (100 ng/ml) or PBS; bars 200 µm. 1045 
Quantification of the number of Tom+ cells in (D) the synovial membrane and (E) repair 1046 
mesenchyme in the defect site. 1047 
 1048 
  1049 
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Supplementary table 1. Ages of operated sheep. COS7-GFP treated group mean age 2.9 years ± 1050 
0.45 (SD); COS7-AGRIN treated group mean age 2.95 years  ± 0.40 (SD). 1051 
Treatment group Age Exclusion 
COS7-GFP 2.6  
COS7-GFP 2.5  
COS7-GFP 3.3  
COS7-GFP 3.6 Osteomyelitis in the forelimb, CT analysis only 
COS7-GFP 2.6 Cyst, CT analysis only 
COS7-GFP 2.8  
COS7-AGRIN 3.4  
COS7-AGRIN 2.5  
COS7-AGRIN 2.5  
COS7-AGRIN 2.8  
COS7-AGRIN 3.3  
COS7-AGRIN 3.2  
 1052 
  1053 
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Supplementary table 2. Antibody supplier and usage information. 1054 
Antibodies Species Code Supplier 
Western 
Blotting Immunofluorescence  
AGRIN Rabbit H300 
Santa Cruz 
Biotechnology   1:100 
CREB Rabbit 9197 Cell Signaling 1:1000 1:800 
pCREB Rabbit 9198 Cell signaling 1:1000  1:800 
GDF5 Rabbit 93855 Abcam   1:1000 
IgG Rabbit 37415 Abcam   1:100-1:800 
AlexaFluro55
5 Goat 150078 ThermoFisher   1:300 
α-TUBULIN Mouse T5168 Sigma 1:5000  
COL2A1 Rabbit 
Ab212
91 Abcam  1:100 
Tomato Goat 
Ab008




379 Rockland  1:600 
  1055 
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Supplementary table 3. Recombinant proteins and reagents supplier and usage information. 1056 
 Recombinant Concentration Resuspended in Code Supplier 
IL-1β 20 ng/ml 
 0.1% BSA in 
PBS  201-LB 
 R&D 
systems 
TNF-α 20 ng/ml 




WNT3A 50-200 ng/ml 






Wnt-9A 200 ng/ml 






SKL2001 10 µM DMSO  681667  Calbiochem 
BIO 10 µM DMSO  3194  Tocris 
MeBIO  10 µM DMSO 3873 Tocris 
Forskolin 10 µM DMSO  F6886  Sigma 
666-15 1 µM DMSO  5661  Tocris 
KN92 10 µM DMSO  4130  Tocris 
KN93 10 µM DMSO  1278  Tocris 




  1058 
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Supplementary table 4. Primer and siRNA sequences 1059 









hAGRN CCTGACCCTCAGCTGGCCCT AGATACCCAGGCAGGCGGCA 136 
hDKK ATTCCAACGCTATCAAGAAC CCAAGGTGCTATGATCATTACC 384 
hGDF5 AGGCAACAGCAGCGTGAAGT GGTCATCTTGCCCTTTGTCAA 77 

















A Stealth RNAi negative control duplex of low GC content was used as a negative control 1060 
(Invitrogen). h:human, b:bovine.   1061 
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R script for download and statistical analysis of microarray data from Comblain et al. (30) 1062 
# Version info: R 3.2.3, Biobase 2.30.0, GEOquery 2.40.0, limma 3.26.8 1063 
# R scripts generated  Wed Sep 4 06:31:58 EDT 2019 1064 
 1065 
################################################################ 1066 





# load series and platform data from GEO 1072 
 1073 
gset <- getGEO("GSE75181", GSEMatrix =TRUE, AnnotGPL=TRUE) 1074 
if (length(gset) > 1) idx <- grep("GPL10558", attr(gset, "names")) else idx <- 1 1075 




# make proper column names to match toptable  1078 
fvarLabels(gset) <- make.names(fvarLabels(gset)) 1079 
 1080 
# group names for all samples 1081 
gsms <- "000000000000XXXXXXXXXXXX111111111111XXXXXXXXXXXX" 1082 
sml <- c() 1083 
for (i in 1:nchar(gsms)) { sml[i] <- substr(gsms,i,i) } 1084 
 1085 
# eliminate samples marked as "X" 1086 
sel <- which(sml != "X") 1087 
sml <- sml[sel] 1088 
gset <- gset[ ,sel] 1089 
 1090 
# log2 transform 1091 
ex <- exprs(gset) 1092 
qx <- as.numeric(quantile(ex, c(0., 0.25, 0.5, 0.75, 0.99, 1.0), na.rm=T)) 1093 
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LogC <- (qx[5] > 100) || 1094 
          (qx[6]-qx[1] > 50 && qx[2] > 0) || 1095 
          (qx[2] > 0 && qx[2] < 1 && qx[4] > 1 && qx[4] < 2) 1096 
if (LogC) { ex[which(ex <= 0)] <- NaN 1097 
  exprs(gset) <- log2(ex) } 1098 
 1099 
# set up the data and proceed with analysis 1100 
sml <- paste("G", sml, sep="")    # set group names 1101 
fl <- as.factor(sml) 1102 
gset$description <- fl 1103 
design <- model.matrix(~ description + 0, gset) 1104 
colnames(design) <- levels(fl) 1105 
fit <- lmFit(gset, design) 1106 
cont.matrix <- makeContrasts(G1-G0, levels=design) 1107 
fit2 <- contrasts.fit(fit, cont.matrix) 1108 
fit2 <- eBayes(fit2, 0.01) 1109 
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tT <- topTable(fit2, adjust="fdr", sort.by="B", number=250) 1110 
 1111 
tT <- subset(tT, 1112 
select=c("ID","adj.P.Val","P.Value","t","B","logFC","Gene.symbol","Gene.title")) 1113 








# load series and platform data from GEO 1122 
 1123 
gset <- getGEO("GSE75181", GSEMatrix =TRUE, getGPL=FALSE) 1124 
if (length(gset) > 1) idx <- grep("GPL10558", attr(gset, "names")) else idx <- 1 1125 
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gset <- gset[[idx]] 1126 
 1127 
# group names for all samples in a series 1128 
gsms <- "000000000000XXXXXXXXXXXX111111111111XXXXXXXXXXXX" 1129 
sml <- c() 1130 
for (i in 1:nchar(gsms)) { sml[i] <- substr(gsms,i,i) } 1131 
sml <- paste("G", sml, sep="")  set group names 1132 
 1133 
# eliminate samples marked as "X" 1134 
sel <- which(sml != "X") 1135 
sml <- sml[sel] 1136 
gset <- gset[ ,sel] 1137 
 1138 
# order samples by group 1139 
ex <- exprs(gset)[ , order(sml)] 1140 
sml <- sml[order(sml)] 1141 
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fl <- as.factor(sml) 1142 
labels <- c("Control","IL-1") 1143 
 1144 
# set parameters and draw the plot 1145 
palette(c("#dfeaf4","#f4dfdf", "#AABBCC")) 1146 
dev.new(width=4+dim(gset)[[2]]/5, height=6) 1147 
par(mar=c(2+round(max(nchar(sampleNames(gset)))/2),4,2,1)) 1148 
title <- paste ("GSE75181", '/', annotation(gset), " selected samples", sep ='') 1149 
boxplot(ex, boxwex=0.6, notch=T, main=title, outline=FALSE, las=2, col=fl) 1150 
legend("topleft", labels, fill=palette(), bty="n") 1151 
 1152 
 1153 
